August 4, 2016
Quest Diagnostics and Inovalon received two gold medals at the 2016 Golden Bridge Awards for Data Diagnostics™, a point-of-care health analytics technology. Data Diagnostics is a suite of individualized analytical reports that physicians can use to enhance patient recommendations. Quest’s 20 billion clinical laboratory test results, combined with Inovalon’s big data analytics platform, allows for data to be analyzed in real time from more than 132 million patients.
Christopher Fikry, vice president of oncology at Quest Diagnostics, will be presenting on challenges associated with the commercialization of companion and complementary diagnostics at the 8th Annual Personalized & Precision Medicine Conference. For more information, visit: http://personalizedmedicinepartnerships.com.
“Data Diagnostics is specifically designed to help providers and health plans more quickly adopt value-based care models”, said Lidia L. Fonseca, senior vice president and chief information officer at Quest Diagnostics. With the hopes in better understanding patient outcomes and financial performance, Quest Diagnostics and Inovalon are quickly on the way to achieving that goal. For more information on Data Diagnostics, visit: http://questdiagnostics.com/2016-07-27.
One of the longest running conferences in the personalized and precision medicine space, Arrowhead’s 8th Annual Personalized & Precision Medicine Conference will be held October 12-13, 2016 in the San Francisco Bay Area. With several key thought leaders like Christopher Fikry, attendees will gain valuable insights into a variety of crucial factors in precision and personalized medicine. For more information, download a brochure at: personalizedmedicinepartnerships.com/brochure.
For more information, contact:
John Waslif: Managing Director
Arrowhead Publishers
866-945-0263 ext 700
This email address is being protected from spambots. You need JavaScript enabled to view it.
Rachel Donlon: Marketing Associate
Arrowhead Publishers
866-945-0263 ext 701
This email address is being protected from spambots. You need JavaScript enabled to view it.